110 related articles for article (PubMed ID: 12431658)
1. Mycophenolate mofetil for the prophylaxis of acute graft-versus-host disease in stem cell transplant recipients.
Kiehl MG; Schäfer-Eckart K; Kröger M; Bornhäuser M; Basara N; Blau IW; Kienast J; Fauser AA; Ehninger G; Armstrong VW; Shipkova M
Transplant Proc; 2002 Nov; 34(7):2922-4. PubMed ID: 12431658
[No Abstract] [Full Text] [Related]
2. Mycophenolate mofetil administered every 8 hours in combination with tacrolimus is efficacious in the prophylaxis of acute graft versus host disease in childhood, adolescent, and young adult allogeneic stem cell transplantation recipients.
Militano O; Ozkaynak MF; Mehta B; van deVen C; Hamby C; Cairo MS
Pediatr Blood Cancer; 2018 Aug; 65(8):e27091. PubMed ID: 29667720
[TBL] [Abstract][Full Text] [Related]
3. The use of mycophenolate mofetil in liver transplant recipients.
Detry O; de Roover A; Delwaide J; Meurisse M; Honoré P
Expert Opin Pharmacother; 2003 Nov; 4(11):1949-57. PubMed ID: 14596648
[TBL] [Abstract][Full Text] [Related]
4. Mycophenolate Mofetil in the treatment of acute and chronic GVHD in hematopoietic stem cell transplant patients: four years of experience.
Basara N; Kiehl MG; Blau W; Römer E; Bischoff M; Schmetzer B; Kirsten D; Günzelmann S; Fauser AA
Transplant Proc; 2001 May; 33(3):2121-3. PubMed ID: 11377471
[No Abstract] [Full Text] [Related]
5. Mycophenolate mofetil and cyclosporine for graft-versus-host disease prophylaxis following reduced intensity conditioning allogeneic stem cell transplantation.
Mohty M; de Lavallade H; Faucher C; Bilger K; Vey N; Stoppa AM; Gravis G; Coso D; Viens P; Gastaut JA; Blaise D
Bone Marrow Transplant; 2004 Sep; 34(6):527-30. PubMed ID: 15286687
[TBL] [Abstract][Full Text] [Related]
6. Response to mycophenolate mofetil therapy in refractory chronic graft-versus-host disease.
Busca A; Locatelli F; Marmont F; Audisio E; Falda M
Haematologica; 2003 Jul; 88(7):837-9. PubMed ID: 12857569
[No Abstract] [Full Text] [Related]
7. Efficacy and safety of mycophenolate mofetil for the treatment of acute and chronic GVHD in bone marrow transplant recipient.
Basara N; Blau WI; Kiehl MG; Römer E; Rudolphi M; Bischoff M; Kirsten D; Sanchez H; Günzelmann S; Fauser AA
Transplant Proc; 1998 Dec; 30(8):4087-9. PubMed ID: 9865306
[No Abstract] [Full Text] [Related]
8. Maximizing the benefits of mycophenolate mofetil as graft-versus-host disease prophylaxis.
Hamilton BK; Kalaycio M
Biol Blood Marrow Transplant; 2014 Nov; 20(11):1869-70. PubMed ID: 25065905
[No Abstract] [Full Text] [Related]
9. Use of intravenous mycophenolate mofetil for graft-versus-host disease prophylaxis in an allogeneic hematopoietic stem cell transplant recipient with an allergic reaction to cyclosporine and tacrolimus.
Dvorak CC; Callard E; Agarwal R
Bone Marrow Transplant; 2006 Aug; 38(3):253-4. PubMed ID: 16785867
[No Abstract] [Full Text] [Related]
10. Cyclosporine A and mycophenolate mofetil vs cyclosporine A and methotrexate for graft-versus-host disease prophylaxis after stem cell transplantation from HLA-identical siblings.
Neumann F; Graef T; Tapprich C; Vaupel M; Steidl U; Germing U; Fenk R; Hinke A; Haas R; Kobbe G
Bone Marrow Transplant; 2005 Jun; 35(11):1089-93. PubMed ID: 15821769
[TBL] [Abstract][Full Text] [Related]
11. The combination of cyclosporine and mycophenolate mofetil is less effective than cyclosporine and methotrexate in the prevention of acute graft-versus host disease after stem-cell transplantation from unrelated donors.
Yerushalmi R; Shem-Tov N; Danylesko I; Shouval R; Nagler A; Shimoni A
Am J Hematol; 2017 Mar; 92(3):259-268. PubMed ID: 28052467
[TBL] [Abstract][Full Text] [Related]
12. Graft-versus-host disease prophylaxis with tacrolimus and mycophenolate mofetil in HLA-matched nonmyeloablative transplant recipients is associated with very low incidence of GVHD and nonrelapse mortality.
Sabry W; Le Blanc R; Labbé AC; Sauvageau G; Couban S; Kiss T; Busque L; Cohen S; Lachance S; Roy DC; Roy J
Biol Blood Marrow Transplant; 2009 Aug; 15(8):919-29. PubMed ID: 19589481
[TBL] [Abstract][Full Text] [Related]
13. Different efficacy of mycophenolate mofetil as salvage treatment for acute and chronic GVHD after allogeneic stem cell transplant.
Kim JG; Sohn SK; Kim DH; Lee NY; Suh JS; Lee KS; Lee KB
Eur J Haematol; 2004 Jul; 73(1):56-61. PubMed ID: 15182339
[TBL] [Abstract][Full Text] [Related]
14. A pilot study of tacrolimus and mycophenolate mofetil graft-versus-host disease prophylaxis in childhood and adolescent allogeneic stem cell transplant recipients.
Osunkwo I; Bessmertny O; Harrison L; Cheung YK; Van de Ven C; del Toro G; Garvin J; George D; Bradley MB; Wolownik K; Wischhover C; Levy J; Skerrett D; Cairo MS
Biol Blood Marrow Transplant; 2004 Apr; 10(4):246-58. PubMed ID: 15077223
[TBL] [Abstract][Full Text] [Related]
15. Decreased risk of acute gastrointestinal toxicity when substituting methotrexate with mycophenolate mofetil in the prevention of graft-versus-host disease in stem cell transplantation following myeloablative conditioning regimens.
Pohlreich D; Vitek A; Maalouf J; Cetkovsky P
Bone Marrow Transplant; 2006 Jan; 37(2):235-6; author reply 236-7. PubMed ID: 16284607
[No Abstract] [Full Text] [Related]
16. A Pilot Study of Continuous Infusion of Mycophenolate Mofetil for Prophylaxis of Graft-versus-Host-Disease in Pediatric Patients.
Windreich RM; Goyal RK; Joshi R; Kenkre TS; Howrie D; Venkataramanan R
Biol Blood Marrow Transplant; 2016 Apr; 22(4):682-689. PubMed ID: 26740371
[TBL] [Abstract][Full Text] [Related]
17. Delayed neutrophil engraftment in cord blood transplantation with intensive administration of mycophenolate mofetil for GVHD prophylaxis.
Okamura A; Shimoyama M; Ishii S; Wakahashi K; Asada N; Kawano H; Kawamori Y; Nishikawa S; Minagawa K; Katayama Y; Matsui T
Bone Marrow Transplant; 2011 Jan; 46(1):148-9. PubMed ID: 20228852
[No Abstract] [Full Text] [Related]
18. An age-dependent pharmacokinetic study of intravenous and oral mycophenolate mofetil in combination with tacrolimus for GVHD prophylaxis in pediatric allogeneic stem cell transplantation recipients.
Bhatia M; Militano O; Jin Z; Figurski M; Shaw L; Moore V; Morris E; Tallamy B; van deVen C; Ayello J; Baxter-Lowe L; Satwani P; George D; Bradley MB; Garvin J; Cairo MS
Biol Blood Marrow Transplant; 2010 Mar; 16(3):333-43. PubMed ID: 19835971
[TBL] [Abstract][Full Text] [Related]
19. Mycophenolate mofetil use after unrelated hematopoietic stem cell transplantation for prophylaxis and treatment of graft-vs.-host disease in adult patients in Japan.
Iida M; Fukuda T; Uchida N; Murata M; Aotsuka N; Minagawa K; Oohashi K; Fukushima K; Kondo T; Eto T; Miyamoto T; Morishima Y; Nagamura T; Atsuta Y; Suzuki R
Clin Transplant; 2014 Sep; 28(9):980-9. PubMed ID: 24943923
[TBL] [Abstract][Full Text] [Related]
20. Total Body Irradiation-Based Myeloablative Haploidentical Stem Cell Transplantation Is a Safe and Effective Alternative to Unrelated Donor Transplantation in Patients Without Matched Sibling Donors.
Solomon SR; Sizemore CA; Sanacore M; Zhang X; Brown S; Holland HK; Morris LE; Bashey A
Biol Blood Marrow Transplant; 2015 Jul; 21(7):1299-307. PubMed ID: 25797174
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
